GSK's RSV, Shingles vaccines show on-par immune response in joint trial
British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...
GSK's RSV vaccine meets main goal when co-administered with shingles shot
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles ...
FiercePharma3 天
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance ...
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...
BioSpace2 天
GSK Builds Combo Case for RSV, Shingles Shots With Phase III Data
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...
emjreviews.com2 天
GSK pursues co-administration of RSV and shingles vaccines
GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...
生物谷6 天
GSK公司季节性流感mRNA疫苗2期临床试验结果积极
6月7日，葛兰素史克（GSK）宣布，FDA批准重组呼吸道合胞病毒（RSV）疫苗Arexvy的适用范围扩大到50-59岁的RSV高危成人。这是首款保护50-59岁高危人群的 ...
The Pharma Letter2 天
Good signs for co administration of GSK’s RSV and shingles vaccines
UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...
GSK posts late-stage trial win for co-administered RSV and shingles vaccines
GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.
GSK报告联合疫苗接种的3期临床试验成功
PHILADELPHIA - GSK plc (LSE/NYSE: GSK)宣布了一项3期临床试验的积极结果,表明AREXVY和SHINGRIX疫苗联合接种与分开接种一样有效。这项针对50岁及以上成年人的研究显示,当呼吸道合胞病毒(RSV)疫苗AREXVY和带状疱疹疫苗SHINGRIX(两者均使用AS01佐剂)一起接种时,免疫反应不劣于分开接种。 该试验的结果计划提交给同行评审的科学出版物和FDA ...
infectiousdiseaseadvisor.com1 天
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
GSK的mRNA流感疫苗进入III期临床试验
GSK plc (LSE/NYSE: GSK)宣布其mRNA季节性流感疫苗的II期临床试验结果成功,标志着该疫苗将进入III期临床试验。这项包括500名不同年龄组参与者的研究显示,该疫苗对甲型和乙型流感病毒株均产生了积极的免疫反应。这标志着GSK的mRNA疫苗项目取得重大进展,有望成为流感领域的新一代最佳疫苗。 该疫苗候选品在年轻人和老年人中均表现出强大的整体抗体滴度和可接受的安全性。这些发现验证 ...
GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the ...